Clinical Trial

Abemaciclib in Patients with Oligodendroglioma

Study Description

Abemaciclib in Patients With Oligodendroglioma

This is a phase II, single arm, open label study looking how well a drug called abemaciclib works in patients with recurrent oligodendroglioma

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Drug - Abemaciclib 200 MG

Subjects will be treated with abemaciclib 200mg by mouth once every 12 hours. Dosing will be continuous and administered on a 28-day cycle

Additional Information

Official Study Title

A Single-Arm, Open-label, Phase II Study Evaluating the Efficacy and Safety of Abemaciclib in Patients With Recurrent Oligodendroglioma

Clinical Trial ID

NCT03969706

ParticipAid ID

aQWGGd